Subcutaneous daratumumab (DARA SC) versus active monitoring in patients (pts) with high-risk smoldering multiple myeloma (SMM): Randomized, open-label, phase 3 AQUILA study.
Overview of attention for article published in Journal of Clinical Oncology, June 2022
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (87th percentile)
-
Good Attention Score compared to outputs of the same age and source (72nd percentile)
Readers on
- mendeley
- 15 Mendeley